Hearing EF Hutton Initiates Coverage On Bone Biologics With Buy Rating And $2.25 Price Target
Portfolio Pulse from Bill Haddad
EF Hutton has initiated coverage on Bone Biologics (BBLG) with a Buy rating and a $2.25 price target.
May 31, 2023 | 8:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bone Biologics receives a Buy rating and a $2.25 price target from EF Hutton.
EF Hutton's initiation of coverage on Bone Biologics with a Buy rating and a $2.25 price target indicates a positive outlook for the stock. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100